Patients’ autologous T cells are manufactured to gain the ability to target and kill lymphoma cells by gammaretroviral or lentiviral transduction of CARs against CD19, which is expressed on the surface of DLBCL cells. This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.